What did FDA do about ineffective Travere kidney drug?

FDA approved Travere’s kidney drug despite no kidney-function improvement

Travere’s kidney disease drug was found not to improve kidney function, but the FDA approved it anyway. The approval is notable because it suggests regulators accepted benefits that were not captured by improvement in kidney-function measures, or relied on other outcomes from the clinical data.

This matters for patients and clinicians because kidney-function endpoints are often used to judge whether a therapy is slowing damage or improving disease control. When a drug does not show that effect, approval implies there may have been evidence of clinically meaningful benefits elsewhere—such as effects on other disease markers, progression, symptom burden, or safety compared with alternatives.

Why this kind of approval can be controversial

When efficacy signals are unclear for a core endpoint, questions typically turn on:

• Which outcomes were considered persuasive for approval.
• How regulators weigh surrogate endpoints versus direct functional improvement.
• What patient population was studied and whether the results generalize.

What to watch next

For this specific case, the key takeaway is the mismatch between an expected benefit (better kidney function) and the observed result, paired with the FDA’s decision to still move forward. Patients starting or considering the therapy may want clinicians to explain what benefit was demonstrated beyond kidney function, and how that fits individual risk.

The provided summary does not include the drug’s name, the exact trial outcomes, or the specific FDA rationale beyond the fact of approval despite lack of kidney-function improvement.